U.S. Markets close in 25 mins

CAD/ARS (CADARS=X)

CCY - CCY Delayed Price. Currency in ARS
Add to watchlist
59.3273+0.2510 (+0.42%)
As of 7:49PM BST. Market open.
Full screen
Previous Close59.076
Open58.917
Bid59.327
Day's Range58.886 - 59.461
52 Week Range43.1081 - 59.4612
Ask59.332
  • Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19
    PR Newswire

    Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

    Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that its anti-SARS-CoV-2 hyperimmune globulin, a potential treatment for COVID-19, has started a randomized controlled clinical trial to test its safety, efficacy and tolerability. This medicine provides a high and consistent concentration of purified neutralizing antibodies and could be used for both prevention and treatment of the disease. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

  • Is Grifols SA (GRFS) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Grifols SA (GRFS) Going to Burn These Hedge Funds?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.
    PR Newswire

    Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

    Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's leading producers of plasma-derived medicines, today announced the closing of its transaction with the South Korean firm, GC Pharma (Group) to acquire a plasma fractionation plant, an immunoglobulin and an albumin purification plants in Montreal (Canada) for US$370 million, and, in a separate transaction, 11 plasma collection centers in the United States property of Green Cross for US$90 million.